Novel thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceuticals containing these compounds
申请人:TEIJIN LIMITED
公开号:EP0051284A1
公开(公告)日:1982-05-12
A novel compound selected from the group consisting of 7-(or 6- or 4-) thiaprostaglandin E1 derivatives of the formula
wherein A represents
- in which n is 0,1 or 2, provided that only one A cut of three is (O)n
; R1- R7 and G are defined in claim 1, the 15-epimers of said thiaprostaglandin E1 derivatives, the enatiomers of said thiaprostaglandin E1 derivatives or their 15-epimers, and mixtures of these compounds,
A 7-thiaprostagiandin E, derivatives and/or its optical isomer may be prepared by reacting a 2-organo-2-cyclopentenone (II) with an organic copper-lithium compound (III) to effect conjugation reaction. A 6-thiaprostaglandin E1 derivative and/or its optical isomer may be prepared by subjecting an α-β-unsaturated ketone (IV) and a thiol (V) to the Michael addition reaction. And 4-thiaprostaglandin derivative and/or its optical isomer may also be prepared by the Michael addition reaction from a 2-allyl substituted cyclopentanone (VI) and a thiol (VIII).
Some compounds ((I)-1) amongst the compounds of the formula (I) and/or their optical isomer are useful for controlling vascularactions such as angina pectoris, vasodilation etc.
选自由式 7-(或 6-或 4-)硫前列腺素 E1 衍生物组成的组的新型化合物
其中 A 代表
- 其中 n 为 0、1 或 2,条件是三个 A 中只有一个是 (O)n
;R1- R7和G在权利要求1中定义,所述硫前列腺素E1衍生物的15-表聚体,所述硫前列腺素E1衍生物的对映体或它们的15-表聚体,以及这些化合物的混合物、
7-硫前列腺素 E 衍生物和/或其光学异构体可通过 2-有机-2-环戊烯酮 (II) 与有机铜锂化合物 (III) 发生共轭反应来制备。6- 硫前列腺素 E1 衍生物和/或其光学异构体可通过使 α-β- 不饱和酮(IV)和硫醇(V)发生迈克尔加成反应来制备。4-硫代前列腺素衍生物和/或其光学异构体也可以由 2-烯丙基取代的环戊酮(VI)和硫醇(VIII)通过迈克尔加成反应制备。
式(I)化合物中的某些化合物((I)-1)和/或其光学异构体可用于控制血管反应,如心绞痛、血管扩张等。
US4466980A
申请人:——
公开号:US4466980A
公开(公告)日:1984-08-21
Synthesis of 7-thiaprostaglandin E1 congeners: Potent inhibitors of platelet aggregation.
Novel 7-thiaprostaglandin E1 derivatives and congeners were synthesized by a stepwise three-component coupling process, which involves the introduction of α-side chains (thiols) and β-side chains (organocopper reagents) into (R)-4-tert-butyldimethylsilyloxy-2-cyclopentenone. Several acid derivatives of 7-thiaprostaglandin E1 were also prepared either by enzymatic or by chemical methods. The stereochemistry of these products was assigned on the basis of the results with chiral protected cyclopentenones and chiral ω-side chains. Some of these 7-thiaprostaglandin E1 congeners were found to exhibit more potent platelet aggregation-inhibitory activity than PGE1. The structure-activity relationship of these congeners is discussed.